Case Report: Infectious prophylaxis in hematological malignancies

Patients with hematological malignancies and past serological evidence of hepatitis B are at risk for HBV reactivation. In myeloproliferative neoplasms, continuous treatment with the JAK 1/2 inhibitor ruxolitinib confers a moderate risk of reactivation (1-10%); nevertheless, no prospective randomize...

Descripción completa

Detalles Bibliográficos
Autores principales: Passucci, Mauro, Masucci, Chiara, Paoletti, Francesca, Ielo, Claudia, Costa, Alessandro, Carmosino, Ida, Scalzulli, Emilia, Martelli, Maurizio, Gentile, Giuseppe, Breccia, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183604/
https://www.ncbi.nlm.nih.gov/pubmed/37197426
http://dx.doi.org/10.3389/fonc.2023.1163175
_version_ 1785041989387943936
author Passucci, Mauro
Masucci, Chiara
Paoletti, Francesca
Ielo, Claudia
Costa, Alessandro
Carmosino, Ida
Scalzulli, Emilia
Martelli, Maurizio
Gentile, Giuseppe
Breccia, Massimo
author_facet Passucci, Mauro
Masucci, Chiara
Paoletti, Francesca
Ielo, Claudia
Costa, Alessandro
Carmosino, Ida
Scalzulli, Emilia
Martelli, Maurizio
Gentile, Giuseppe
Breccia, Massimo
author_sort Passucci, Mauro
collection PubMed
description Patients with hematological malignancies and past serological evidence of hepatitis B are at risk for HBV reactivation. In myeloproliferative neoplasms, continuous treatment with the JAK 1/2 inhibitor ruxolitinib confers a moderate risk of reactivation (1-10%); nevertheless, no prospective randomized data are available to strongly recommend HBV prophylaxis in these patients. Here, we report a case of primary myelofibrosis and past serological evidence of HBV infection, treated with ruxolitinib and concomitant lamivudine, developing HBV reactivation due to premature withdrawal of prophylaxis. This case underlines the potential need for persistent HBV prophylaxis in the setting of ruxolitinib treatment.
format Online
Article
Text
id pubmed-10183604
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101836042023-05-16 Case Report: Infectious prophylaxis in hematological malignancies Passucci, Mauro Masucci, Chiara Paoletti, Francesca Ielo, Claudia Costa, Alessandro Carmosino, Ida Scalzulli, Emilia Martelli, Maurizio Gentile, Giuseppe Breccia, Massimo Front Oncol Oncology Patients with hematological malignancies and past serological evidence of hepatitis B are at risk for HBV reactivation. In myeloproliferative neoplasms, continuous treatment with the JAK 1/2 inhibitor ruxolitinib confers a moderate risk of reactivation (1-10%); nevertheless, no prospective randomized data are available to strongly recommend HBV prophylaxis in these patients. Here, we report a case of primary myelofibrosis and past serological evidence of HBV infection, treated with ruxolitinib and concomitant lamivudine, developing HBV reactivation due to premature withdrawal of prophylaxis. This case underlines the potential need for persistent HBV prophylaxis in the setting of ruxolitinib treatment. Frontiers Media S.A. 2023-05-01 /pmc/articles/PMC10183604/ /pubmed/37197426 http://dx.doi.org/10.3389/fonc.2023.1163175 Text en Copyright © 2023 Passucci, Masucci, Paoletti, Ielo, Costa, Carmosino, Scalzulli, Martelli, Gentile and Breccia https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Passucci, Mauro
Masucci, Chiara
Paoletti, Francesca
Ielo, Claudia
Costa, Alessandro
Carmosino, Ida
Scalzulli, Emilia
Martelli, Maurizio
Gentile, Giuseppe
Breccia, Massimo
Case Report: Infectious prophylaxis in hematological malignancies
title Case Report: Infectious prophylaxis in hematological malignancies
title_full Case Report: Infectious prophylaxis in hematological malignancies
title_fullStr Case Report: Infectious prophylaxis in hematological malignancies
title_full_unstemmed Case Report: Infectious prophylaxis in hematological malignancies
title_short Case Report: Infectious prophylaxis in hematological malignancies
title_sort case report: infectious prophylaxis in hematological malignancies
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183604/
https://www.ncbi.nlm.nih.gov/pubmed/37197426
http://dx.doi.org/10.3389/fonc.2023.1163175
work_keys_str_mv AT passuccimauro casereportinfectiousprophylaxisinhematologicalmalignancies
AT masuccichiara casereportinfectiousprophylaxisinhematologicalmalignancies
AT paolettifrancesca casereportinfectiousprophylaxisinhematologicalmalignancies
AT ieloclaudia casereportinfectiousprophylaxisinhematologicalmalignancies
AT costaalessandro casereportinfectiousprophylaxisinhematologicalmalignancies
AT carmosinoida casereportinfectiousprophylaxisinhematologicalmalignancies
AT scalzulliemilia casereportinfectiousprophylaxisinhematologicalmalignancies
AT martellimaurizio casereportinfectiousprophylaxisinhematologicalmalignancies
AT gentilegiuseppe casereportinfectiousprophylaxisinhematologicalmalignancies
AT brecciamassimo casereportinfectiousprophylaxisinhematologicalmalignancies

Ejemplares similares